Evidence map›Paper›PMID 30279553›Full record

ArticleScientific reports2018

Arrowtail RNA for Ligand Display on Ginger Exosome-like Nanovesicles to Systemic Deliver siRNA for Cancer Suppression.

Zhefeng Li, Hongzhi Wang, Hongran Yin, Chad Bennett, Huang-Ge Zhang, Peixuan Guo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 164 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
164citing papers in PubMed, 3 pooled it
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

164 citing papers in PubMed, 3 syntheses or guidelines pooled it, 238 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Exosome-mediated siRNA delivery in cancer: Loading strategies, targeting approaches, and therapeutic outcomes.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026
    Review
  6. Exosome-mediated siRNA delivery in cancer: Loading strategies, targeting approaches, and therapeutic outcomes.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026
    Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

104 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Zhefeng LiCenter for RNA Nanobiotechnology and Nanomedicine, College of Pharmacy, Division of Pharmaceutics and Pharmaceutical Chemistry, College of Medicine, Dorothy M. Davis Heart and Lung Research Institute, NCI Comprehensive Cancer Center, The Ohio State University, Columbus, OH, 43210, USA.
Hongzhi WangCenter for RNA Nanobiotechnology and Nanomedicine, College of Pharmacy, Division of Pharmaceutics and Pharmaceutical Chemistry, College of Medicine, Dorothy M. Davis Heart and Lung Research Institute, NCI Comprehensive Cancer Center, The Ohio State University, Columbus, OH, 43210, USA.
Hongran YinCenter for RNA Nanobiotechnology and Nanomedicine, College of Pharmacy, Division of Pharmaceutics and Pharmaceutical Chemistry, College of Medicine, Dorothy M. Davis Heart and Lung Research Institute, NCI Comprehensive Cancer Center, The Ohio State University, Columbus, OH, 43210, USA.
Chad BennettMedicinal Chemistry Shared Resource, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, 43210, USA.
Huang-Ge ZhangJames Brown Cancer Center, Department of Microbiology & Immunology, University of Louisville, Louisville, KY, USA.
Peixuan GuoCenter for RNA Nanobiotechnology and Nanomedicine, College of Pharmacy, Division of Pharmaceutics and Pharmaceutical Chemistry, College of Medicine, Dorothy M. Davis Heart and Lung Research Institute, NCI Comprehensive Cancer Center, The Ohio State University, Columbus, OH, 43210, USA. guo.1091@osu.edu.
The Ohio State University · USUNC Lineberger Comprehensive Cancer CenterUniversity of Louisville · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
Optimizing RNA nanoparticles size and shape for enhancing cancer targeting and treatmentU01CA207946 · NCI · OHIO STATE UNIVERSITY · PI CARSON, WILLIAM E., GUO, PEIXUAN · 2016 to 2020
$2.7M
Fruit exosome-like particles for therapeutic delivery of extracellular miRNAsUH3TR000875 · NCATS · UNIVERSITY OF LOUISVILLE · PI ZHANG, HUANG-GE · 2015 to 2017
$2.7M
RNA Therapeutics for Targeted Treatment of Colon CancerR01CA186100 · NCI · UNIVERSITY OF HOUSTON · PI GUO, BIN · 2015 to 2018
$1.4M
NCATS NIH HHS UH3 TR000875NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA186100NCI NIH HHS U01 CA207946
6 · The paper itself

Abstract

Exosomes have shown increasing potential as delivery vesicles for therapy, but challenges like cost/yield, drug payload, and targeting specificity still exist. Plant derived exosome-like nanoparticles have been reported as a promising substitution and exhibit biocompatibility through oral, intranasal administration; however, systemic delivery of siRNA by exosome-like nanoparticles directly isolated from plants has not been reported. Recently, we reported the control of RNA orientation to decorate human derived exosome with cell targeting ligands for specific delivery of siRNA to tumors. Here, we expand to the application of arrowtail RNA nanoparticles for displaying ligands on ginger derived exosome-like nanovesicles (GDENs) for siRNA delivery and tumor inhibition through IV administration. Cushion ultracentrifugation coupled with equilibrium density gradient ultracentrifugation were used for purifying GDENs that displayed size, density, and morphology similar to human derived exosomes. Folic acid (FA), as a ligand, was displayed on the surface of GDENs for targeted delivery of survivin siRNA to KB cancer models. In vitro gene knockdown efficacy by FA-3WJ/GDENs/siRNA complex was comparable to transfection. We observed inhibition of tumor growth on a xenograft model by intravenous administration, which reveals the potential of GDENs as an economic delivery system for siRNA.

Indexed as

AnimalsCell Line, TumorDrug CarriersExosomesFolic AcidHEK293 CellsHumansMiceMice, NudeNanoparticlesNeoplasmsRNA, Small InterferingSurvivinXenograft Model Antitumor AssaysZingiber officinaleDrug CarriersFolic AcidRNA, Small InterferingSurvivin

Identifiers

PMID30279553
PMCPMC6168523
OpenAlexW2892812964

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.